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Objectives Sexually transmitted diseases (STDs) and anogenital cancers are the major health problems in
Indian women but no reliable estimate of the prevalence of either genital chlamydial infection or human
papillomavirus (HPV) infection in STD patients is available. The aim of this study was to detect the frequency
of Chlamydia trachomatis and the most prevalent high-risk HPV type 16 (HPV 16) infection in Indian women,
with STDs and precancerous and cancerous lesions of the uterine cervix by polymerase chain reaction (PCR),
and their comparison with those of conventional serology and antigen tests used for C. trachomatis detection.
Methods Endocervical swabs or scrapes were collected from 50 women with STDs and 30 normal healthy
women attending the STD clinics of Smt. Sucheta Kripalani Hospital, New Delhi. Scraped cervical cell
specimens were also collected from 50 women with precancerous and cancerous lesions of the uterine cervix.
Detection of C. trachomatis and HPV was carried out by PCR using chlamydia and HPV genome-specific
oligonucleotide primers. The detection of chlamydial antigen and IgG-specific antibodies was carried out by
enzyme immunoassay (EIA) and serological enzyme-linked immunosorbent assay (ELISA), respectively.
Results A chlamydia plasmid-based PCR assay detected 50% (25 of 50) positivity of C. trachomatis in STD
patients and HPV 16 DNA was found in 30% (15 of 50) of these cases which are significantly higher than those
found in healthy controls. The PCR estimate of chlamydia was found to be higher than its reported frequency
by tissue culture. The EIA could detect chlamydial antigen in only 13 cases (26%) while serological ELISA
revealed evidence of chlamydia IgG-specific antibodies in 26 (52%) cases. Interestingly, in women with
precancerous and cancerous lesions, the rate of HPV 16 infection was very high (52% and 72%, respectively),
whereas the frequency of chlamydia infection was found to be 12–22% only. Occurrence of other sexually
transmitted agents was also evaluated in the women.
Conclusions This is the first PCR estimate of genital chlamydial (50%) and HPV 16 (30%) infection in STD
patients and women with precancerous and cancerous lesions of the uterine cervix in India. The PCR method
seems to be a good alternative to tissue culture.
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INTRODUCTION
Chlamydia trachomatis, an obligate intracellular Gram negative
bacterium, is one of the most common sexually transmitted
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agents which causes a wide spectrum of diseases including uter-
ine cervical lesions [1,2] in humans. It also causes ocular
disorders, such as trachoma and conjunctivitis. Infants born to
pregnant mother with genital chlamydial infection are also often
at risk of developing conjunctivitis and pneumonia. Chlamydia
trachomatis infection may lead to serious sequelae such as endo-
metritis and salpingitis which often cause infertility in women
[3,4]. The serotypes D to K of C. trachomatis are mainly
associated with sexually transmitted diseases (STDs). Epidemio-
logical studies have revealed a prevalence of the bacteria in
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about 5% of normal population at large although this frequency
is reported to vary between 20 and 40% in STD patients [5–7].
However, chlamydial infections are often asymptomatic which
could contribute to further spread of the disease. Therefore a
sensitive, rapid and reliable method for early diagnosis of C.
trachomatis infection is important for treatment with antibiotics.
In India, sexually transmitted diseases and anogenital cancers
are the major health problems in women. Annually about
100 000 women develop cervical cancer and approximately,
40–50% are infected with one or the other sexually transmitted
agents [8]. A high prevalence of human papillomaviruses
(HPVs) and their role in the development of cancer of the
uterine cervix have been well-documented in Indian women
[9,10] but no reliable estimate of the prevalence of genital
chlamydial infection is available. Furthermore, no information
is available on the prevalence of HPV in STD patients in India.
Using conventional serological and antigen detection assays, a
prevalence rate of 30 to as high as 81% has been reported for
chlamydia in asymptomatic women [11–13]. There is, so far,
only one report of cell culture from India which showed the
prevalence of chlamydial infection to be about 40% in STD
patients [14].
Since all these conventional diagnostic serology or immuno-
assays, including the cell culture methods, are associated with
one or other limitation [15,16] and no polymerase chain reac-
tion (PCR) assay has been employed, we have used a plasmid-
based PCR for the detection of C. trachomatis in endocervical
smear/scrape specimens of women with STD as well as pre-
cancerous and cancerous lesions of the uterine cervix. In
addition, diagnosis was carried out for the ‘high-risk’ HPV type
16 (HPV 16)which is almost exclusively prevalent in the Indian
population and is considered to be a major etiologic agent for
the development of cervical cancers [8,17] in women.
MATERIALS AND METHODS
Study groups
Endocervical swabs or scrapes were collected from 50 symp-
tomatic women aged between 15 and 44 years (mean age
27.2 2 9 years) who were attending the STD clinics of
Smt.Sucheta Kripalani Hospital, New Delhi. Thirty normal
healthy women of similar age group (28 2 8.5 years) with
no previous or present history of promiscuity, STD or other
infectious diseases attending hospital out-patient-department
for either birth control information or other health check-ups
were included as controls. In addition, 50 women (mean age,
30 2 9.6 years) with precancerous (mild or moderate dysplasia)
and 50 (mean age, 33.2 2 8 years) with cancerous lesions of
the uterine cervix were recruited from Lok Nayak hospital,
New Delhi and scraped cells were collected. All the women
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were subjected to thorough clinical examination and a case
history was recorded. All information regarding similar age
group, marital status, socio-economic condition, occupation,
parity, age at marriage, obstetric history, history of any sexually
transmitted diseases in herself or in her husband and the method
of contraception used, etc. were collected. Those who had
received antibiotics in the last 4 weeks were excluded from the
study.
Specimen collection
The ectocervix was first cleaned with a cotton swab to remove
excess mucus and exudate. Three endocervical swabs were
obtained for (i) microscopic examination of pus cells (ii) for
culture of other pathogens, namely gonorrhea, genital herpes
virus (HSV2), candidiasis, bacterial vaginosis, etc. and (iii) for
antigen detection of C. trachomatis. Endocervical cell scrapings
were obtained by rotating the Ayer’s spatula at 180° in the
endocervical canal and transferred to 15 mL plastic vials con-
taining 5 mL of sterile phosphate buffered saline (PBS ) and
stored at 70 °C in a deep freezer until isolation of DNA for
PCR assay. In addition, 5 mL of peripheral venous blood was
collected from each patient for chlamydial serology, ELISA for
HIV and VDRL (Veneral Disease Research Laboratory) test.
Serological tests
Serological tests were carried out for the detection of IgG
specific antibodies to C. trachomatis antigen in patients’ sera by
enzyme immunoassay [18] (Chlamydia IgG; Melotest, Barce-
lona, Spain). The assay utilizes an inactivated specific antigen
coated on to microtiter wells, which binds to the specific anti-
bodies present in the samples. An antihuman IgG antibody
contained in the antibody-enzyme (horse radish–peroxidase)
conjugate solution, binds to the antibodies in the test sample
and finally the color development was measured at 450 nm
using a spectrophotometer. The samples with concentration
less than 9 A.I.U/mL was considered antibody negative, 9–
11 A.I.U/mL as equivocal and more than 11 A.I.U/mL was
taken as antibody positive.
Antigen assay
Detection of C. trachomatis antigen in endocervical specimens
was carried out by ELISA using a Chlamydia ELISA kit (CEL-
ISA) [19–21] (Cellabs Pty. Ltd, Brookvale, NSW, Australia),
which detects chlamydial lipopolysaccharide (LPS) that binds
to the microtitration strips. Monoclonal antibodies added in
the subsequent step bind to the LPS, if present. A peroxidase
conjugated antimouse antibody was added in the third step
binds to any antigen-antibody complexes in the microwells.
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The substrate used was 3,3,5,5? tetramethyl benzidine (TMB)
which produces a blue-colored product in the positive wells.
The absorbances were read at 450 nm using a microwell plate
in a spectrophotometer. For each run, one positive and two
negative controls were included.
DNA extraction
DNA was extracted by a nonorganic method as described pre-
viously by us [22]. Briefly,the scraped cervical cells were washed
once in 1 mL of cold PBS and twice in chilled Tris-Triton
buffer (TTB) containing 10 mM Tris-HCl (pH 8.0), 10 mM
MgCl2, 300 mM Sucrose and 0.8% Triton X-100. The cell pellet
was again washed in cold Tris-EDTA buffer (TEB) containing
10 mM Tris-HCl (pH 8.0), 10 mM EDTA and 10 mM NaCl.
Finally, the cell pellet was resuspended in 200 mL TE buffer
supplemented with 1.25 mg/mL proteinase-K (Boehringer
Mannheim, Germany) and incubated at 65 °C water bath for 2 h.
This DNA solution was directly used for PCR amplification.
Polymerase chain reaction
The PCR was carried out for amplification of a 201 bp sequence
of the cryptic chlamydia plasmid extending from 4761 to 4961 bp
(EMBL Gene Bank accession number 4133141) using the fol-
lowing primers: CC3–5?-TAG TAA CTG CCA CTT CAT
CA-3? and CC4–5?-TTC CCC TTG TAA TTC GTT GC-3?.
The primer sequences were synthesized by an AB1 DNA
synthesizer (Model 381 A; Applied Biosystems Inc, Foster City,
CA, USA) and PCR amplification was carried out in a DNA
thermal cycler (Perkin Elmer Cetus, Roche, NJ, USA) using
Taq DNA polymerase (Amplitaq: Cetus Corporation, Fostep
City, CA, USA). The amplifications were carried out in a 50 mL
reaction mix containing 1 mg sample DNA, 67 mM Tris-HCl
(pH 8.8), 6.7 mM MgCl2, 16.7 mM ammonium sulphate,
6.0 mM EDTA (pH 8.0), 2.5 mM dNTPs (dATP, dCTP, dTTP,
dGTP), 1 mM each of Chlamydia primers CC3 and CC4 and
0.5 units of Taq DNA polymerase (Cetus). The reaction mix-
ture was overlayered with 50 mL mineral oil to prevent evap-
oration. The PCR amplifications were performed for 35 cycles,
each with 30 s of denaturation at 94 °C, annealing at 55 °C and
extension at 72 °C except the first cycle when denaturation was
done for 5 min. In the last cycle extension at 72 °C was pro-
longed for 5 min. Detection of HPV 16 DNA sequences was
carried out using primers from its conserved upstream regu-
latory region (URR). The HPV 16 primers which gave ampli-
mer of 247 bp were as follows: URR-1 5?-AAG GCC AAC
TAA ATG TCA C–3? and URR-2 5?-CTG CTT TTA TAC
TAA CCG G-3?.
The PCR amplification procedures were followed as
described elsewhere [10,23]. The quality of DNA was checked
by simultaneous amplification of the b-globin gene in all the
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samples. The b-globin primer sequences were: b-globin-1 5?
GAA GAG CCA AGG ACA GGT AC 3? and b-globin-2 5?
CAA CTT CAT CCA CGT TAC ACC-3?.
The amplimer size was 268 bp. The desired positive signals
visualized as PCR amplimers of 201 bp (Figure 1a) and 217 bp
(Figure 1b) for C. trachomatis and HPV 16, respectively, in a 3%
Nusieve-agarose gel (FMC BioProducts, Rockland, ME, USA)
were reconfirmed following their transfer and hybridization
with specific DNA probes in Southern blot hybridization.
Figure 1a Detection of Chlamydia trachomatis plasmid-specific
amplification by polymerase chain reaction. Lane 1 is positive con-
trol for C. trachomatis and lanes 2–8 are the cases. Lanes 3, 4, 6 and
8 show amplification of a C. trachomatis specific 201 bp product
along with 268 bp amplimer for the b-globin gene as internal control.
Lanes 2, 5 and 7 are negative for chlamydia showing amplification
of only b-globin gene but absence of chlamydia-specific amplimer.
The extreme left lane is Hae III-digested ox174 DNA size marker.
Figure 1b Polymerase chain reaction amplification of human pap-
illomavirus type 16 (HPV 16) DNA along with b-globin gene
sequences in endocervical scrapes of patients with sexually trans-
mitted diseases. First lane is Hae III digested ox 174 DNA size marker.
Lane 1 is placental DNA showing b-globin gene (268 bp) ampli-
fication. Lane 2 is Cacx DNA showing HPV 16 gene (217) ampli-
fication. Lane 3–5 are endocervical scrapes showing positivity of
HPV 16 and b-globin gene while lane 6 is negative for HPV 16.
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RESULTS
The results of the PCR analysis of C. trachomatis and HPV 16
in 50 cases of symptomatic women with STD along with 30
asymptomatic healthy normal controls are presented in Table 1.
The patients were in the age group of 15–44 years, the mean
age being 27.2 2 9 years and the majority (32 of 50, 64%) were
in the reproductively active age group of 25–34 years. Forty-
five patients (90%) were married and interestingly, only five
(10%) had a history of pre- or extramarital contacts and 46 (92%)
women had a single partner. Further elicitation of information
revealed that a history of concomitant sexually transmitted dis-
eases present in 16 (32%) women and a history of promiscuity
was revealed in 21 (42%) sexual partners.
Of 50 cases of STD studied, 25 (50%) were positive for
Chlamydia whereas only 15 (30%) patients showed presence of
high-risk HPV 16 DNA sequences as revealed by chlamydia and
HPV 16 genome-specific PCR products in ethidium bromide
stained gel (Figure 1a, b). The frequencies were highly sig-
nificant (P  0.001) when compared with those of the controls
(Table 1). Enzyme immunoassay for chlamydia antigen alone
could detect evidence of chlamydia positivity only in 13 (26%)
cases of which 11 (22%) were found to be positive by PCR.
An additional 14 (28%) antigen-negative cases were also PCR
positive. Only two (4%) cases were antigen positive but PCR
negative. The control women showed 3% positivity for chla-
mydia by PCR. Specific IgG antibodies against C. trachomatis
in serological ELISA was detected in 26 (52%) women of whom
only 16 were positive by PCR. Interestingly, the remaining
nine PCR-positive women (the total being 25) were derived
from the 24 antibody-negative patients, whereas 10 patients
who were positive for antibody test were negative by PCR.
Analysis of C. trachomatis as well as HPV in cervical precancer
and cancer cases revealed a low frequency of C. trachomatis in
both cancer (22%) and precancerous (12%) lesions whereas the
frequency of HPV16 was found to be 52 and 72%, respectively.
The difference was found to be highly significant (P  0.001).
Among the 50 cases of endocervicitis patients analyzed, 39
(78%) patients concomitantly had sexually transmitted diseases
such as syphilis, gonorrhoea, herpes progenitalis, bacterial vag-
inosis, etc., and 11 patients had no history of STDs. Among the
chlamydia-infected patients, the majority of them (12 of 25,
Table 1 Detection of Chlamydia trachomatis and human papillomavirus type 16 (HPV 16) DNA sequences in women with
sexually transmitted diseases, by polymerase chain reaction
Subjects Micro-organism No. (%) positive Chl + HPV+ Chl-HPV+ Chl-HPV+ Chl-HPV-
STD’s C. trachomatis 25 (50) 7 (14) 18 (36) 8 (16) 19 (38)
(n = 50) HPV 16 15 (30) – – – –
Controls C. trachomatis 1 (3.3) – – – –
(n = 30) HPV 16 4 (13.3) – – – –
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48%) also had syphilis besides other concomitant sexually trans-
mitted infections. Interestingly, five of 11 with no history of
STD were also found to have chlamydial infections.
DISCUSSION
Polymerase chain reaction is considered to be the most sensitive
and specific diagnostic method employed for detecting infec-
tious agents including C. trachomatis [24–28]. In India, only a
few studies have taken place and this is the first report of a
C. trachomatis PCR assay showing the frequency of genital
chlamydial infection to be 50% in Indian women with STDs.
In contrast, a single study which used a tissue-culture method
revealed 41% positivity for chlamydia [13]. Although the stan-
dard for detection of C. trachomatis has been the cell culture
[29,30], several clinical and technical factors can lead to false
negative results in the culture system [31]. Much care and
precision are therefore required for collection, transport, storage
and processing of cervical specimens for tissue culture. Fur-
thermore, the culture method is time-consuming, expensive
and inapplicable for screening large number of samples at a
time. In contrast, several reports [26,28,32,33] including the
present data indicate that PCR could serve as a good alternative
to tissue culture.
Antigen assay, which is commonly used for C. trachomatis
detection, appears to be an easier method but it is considerably
less sensitive than cell culture. This is evident from the present
finding that C. trachomatis antigen could be detected in only
26% (13 of 50) of cases and of these only 11 (22%) could be
confirmed by PCR. It is possible that the antigen test may not
recognize all chlamydia serovars and hence the results obtained
by this test may not be reliable. Serological detection of IgG
antibody to C. trachomatis is also limited by interspecies cross-
reactivity leading to a substantial number of false positive or
negative results. There is also a high background prevalence of
antibodies to C. trachomatis. Therefore the diagnostic value of
a single high titre of antichlamydial antibodies of IgG class or
any other stable high titre is uncertain. A majority of antibody-
positive or -negative cases could not be reconfirmed by PCR.
This may be because of either past infection or the antibody
titre was decreased to a level undetectable by ELISA.
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It is interesting to note that majority of chlamydia-infected
patients also had syphilis (12 of 25, 48%) besides other con-
comitant sexually transmitted infections such as gonorrhea,
genital herpes simplex virus type-2, condyloma acuminata, can-
didiasis, bacterial vaginosis, etc. It has been mostly observed
that the sexual transmission of HIV infections are generally
higher in STD patients [34–37] but serologically it is interesting
that no HIV-positive case could be detected in the present
study group of STD patients in spite of the fact that HIV
infection shows an increasing trend in India [38].
Chlamydia infections may be associated with inflammatory
changes in the cervical epithelium, particularly friability of the
cervix which has been observed in 16 (45.7%) cases. The preva-
lence of high-risk HPV 16 is found to be 30% among women
with STDs. This is to our knowledge the first report of the
frequency of HPV in STD patients from India. This observation
is very important since HPV 16 is the type almost exclusively
(90%) prevalent in India [10] and it has been observed that
asymptomatic women who harbor high-risk HPV 16 are shown
to have a high rate of progression to malignancy [39; Das
et al. unpublished]. Such a test, allows early identification of a
population at high risk of developing cervical cancer.
It would also be very interesting to see if there is any syner-
gestic effect when both chlamydia and HPV are present in
comparison with infection of HPV alone during development
of cervical cancer. Observation of a slightly higher rate of
chlamydia infection in cancer cases when compared with that
of controls or precancers indicates that C. trachomatis may play
a role as a cofactor with regard to the pathological aggressiveness
of the disease.
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